Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Restoring blood flow to coronary arteries as quickly as possible is the best way to reduce
the damage to the muscle that occurs with a heart attack. However, up to 25-50% of patients
who have angioplasty may have ongoing damage to the heart muscle when the blockage is opened
and blood flow is restored. Complications which may result from this ongoing damage include a
larger area of damaged muscle in the heart, enlargement of the heart, an increased risk of
death, and an increased risk of heart failure. Some of the ongoing damage may involve
increased levels of the protein kinase C (PKC) enzyme. KAI-9803 is a selective inhibitor of
delta PKC. In this study, delta PKC is used with angioplasty and other standard procedures to
restore blood flow after a heart attack. This study is designed to evaluate safety of
different amounts of KAI-9803 when used in treating heart attack patients undergoing
angioplasty. We will also try to evaluate whether KAI-9803 can reduce the amount of heart
muscle damage and the complications that may occur in these patients.